Teva (TEVA) Q1 FY26 earnings call

Teva delivered a solid first quarter, driven by robust growth in its innovative portfolio, notably AUSTEDO, UZEDY, and AJOVY, which helped offset expected declines in generic revenues. The company announced the strategic acquisition of Emalex Bioscience, adding a promising Tourette syndrome asset to its CNS franchise, while reaffirming its 2026 outlook and commitment to 2027 financial targets and balance sheet discipline.